Validated Modalities & Standardized Assessment Portfolios

PVCTS implements hands-on training and investigator certification modules across a broad spectrum of peer-reviewed visual testing parameters. Our methodologies secure perfect data consistency, blocking operational noise from slipping into electronic data capture sheets.

Our standardized certification tracking encompasses:
• **BCVA:** Best Corrected Visual Acuity logMAR baseline metrics.
• **BRVT:** The Berkeley Rudimentary Vision Test array for low-vision ranges.
• **IReST:** International Reading Speed Texts across multiple language structures.
• **LCVA:** Low Contrast Visual Acuity lines utilizing calibrated illuminator cabinets.
• **MNRead:** Proportional continuous text blocks tracking reading velocity thresholds.
• **Pelli-Robson:** Gold-standard single-size letter contrast sensitivity matrices.
• **Teller Acuity Cards:** Preferential looking square-wave gratings for pediatric assessment.

Upcoming International Congress Placements

Coordinate an on-site consultation with our clinical specialists at our exhibition pavilion. Stop by our booth to pick up a complimentary **Precision Vision® Conversion Pocket Card**—a durable, handy reference tool designed to instantly transpose low-contrast thresholds, ICD-9/ICD-10 vision loss tracking metrics, and global notation scales:

• India Society for Clinical Research (ISCR)
  February 24–25 • New Delhi, India
• ARVO Annual Meeting
  April 23–27 • New Orleans, LA • Booth 508

Q: Does PVCTS turn away early-stage feasibility trials, or studies restricted to a very limited number of clinical sites?

A: Absolutely not. No trial configuration is too small or too massive for our logistics pipeline. PVCTS proudly manages global studies ranging across the complete clinical lifecycle—from specialized 3-site feasibility programs up to 350+ site Phase III post-market tracking protocols.

“My career in ophthalmology launched when I was hired as a technician in a single-physician general practice after college. Patients presented with deeply varied path-structures, but they shared an overriding terror: the fear of losing their eyesight. Vision is the singular sensory input humanity generally fears losing the most. Years later, while working with a corneal device laboratory, we commercialized an artificial cornea for legally blind cohorts. We treated an older individual blinded by severe bilateral chemical burns during youth, who had never resolved the facial features of their spouse or children. Following surgery, for the first time in their life, they could see their family members, the home they lived in, and the garden plot where they sat. These are inputs many take for granted. For me, the supreme reward of clinical research remains the power to provide hope while actively preserving and improving global sight thresholds.”